Gene Therapy Not Cost-Effective for Sickle Cell by Conventional Measures

MONDAY, June 5, 2023 -- For persons with sickle cell disease (SCD), gene therapy seems not to be cost-effective per conventional cost-effectiveness analysis (CEA) standards and can be equitable per distributional CEA (DCEA) standards, which...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news